Hypera SA (HYPMY) AI Stock Analysis

• Market Cap: $2.79B
• Dividend Yield: 3.11%
• Average Volume (3M): 341.00
• Price to Earnings (P/E): 18.5
• Beta (1Y): 0.60
• Revenue Growth: -25.84%
• EPS Growth: -55.94%
• Country: US
• Employees: 10,481
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.04
• Shares Outstanding: 633,420,840
• 10 Day Avg. Volume: 90
• 30 Day Avg. Volume: 341
• PEG Ratio: -0.30
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 9.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Hypera SA's overall stock score reflects a balanced outlook. While the company demonstrates strong technical momentum and a stable balance sheet, challenges in revenue and margin pressures temper the optimistic view. The earnings call highlights both substantial achievements in market expansion and product launches, as well as concerns over declining net revenue and gross margins. The valuation remains reasonable, with an attractive dividend yield supporting the stock's appeal. Key risks include maintaining operational efficiency and navigating competition in the generics market.

Hypera SA Business Overview & Revenue Model

Company Description

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

How the Company Makes Money

Hypera SA generates revenue primarily through the sale of its pharmaceutical products across different segments. The company's revenue model is centered on manufacturing and distributing both branded and generic medications to pharmacies, hospitals, and healthcare providers. Key revenue streams include prescription medications, which are sold through healthcare professionals, and OTC products, which are sold directly to consumers through retail channels. Significant partnerships with healthcare institutions and a strong distribution network contribute to the company's earnings. Additionally, Hypera SA invests in research and development to innovate and expand its product offerings, which helps sustain its market position and revenue growth.

Hypera SA Financial Statement Overview

Summary

Hypera SA demonstrates a mixed financial performance. The income statement reflects pressure on profitability with declining margins and revenue. The balance sheet remains robust with a strong equity ratio and manageable debt levels, ensuring financial stability. However, the cash flow statement indicates challenges in sustaining previous cash flow growth. The company must focus on improving operational efficiency and cash management to enhance shareholder value.

Income Statement

Hypera SA's income statement reveals a declining revenue trend with a decrease from 2024 to TTM (Trailing-Twelve-Months). The gross profit margin stands strong at 56.39%, indicating effective cost management. However, the net profit margin has dropped to 12.08%, reflecting challenges in controlling operational costs. The notable fall in EBIT and EBITDA margins to 7.67% and 21.28% respectively signifies pressure on operational efficiency.

Balance Sheet

The company's balance sheet shows a healthy equity ratio of 48.26%, indicating solid financial stability. The debt-to-equity ratio is at 0.79, suggesting a manageable level of leverage. However, the return on equity has decreased to 6.89%, pointing towards reduced profitability for shareholders relative to past performance.

Cash Flow

Cash flow analysis shows a drop in free cash flow and operating cash flow, with a notable decline in free cash flow to net income ratio at 1.73. The operating cash flow to net income ratio at 2.75 suggests strong cash generation ability, but the free cash flow growth rate has turned negative, reflecting challenges in maintaining previous cash flow levels.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.70B	7.44B	7.91B	7.55B	5.94B	4.09B
	Gross Profit
3.78B	4.38B	5.00B	4.76B	3.80B	2.63B
	EBIT
513.51M	1.80B	2.29B	2.64B	2.04B	1.40B
	EBITDA
1.43B	2.23B	2.88B	2.77B	2.16B	1.42B
	Net Income Common Stockholders
808.80M	1.34B	1.65B	1.70B	1.33B	1.30B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.17B	1.74B	2.58B	2.86B	2.29B	4.74B
	Total Assets
28.15B	24.56B	24.51B	23.76B	19.82B	17.25B
	Total Debt
10.79B	9.40B	9.96B	9.68B	7.41B	5.59B
	Net Debt
7.62B	7.66B	7.38B	6.82B	5.12B	847.97M
	Total Liabilities
16.43B	12.46B	12.99B	13.10B	9.98B	8.01B
	Stockholders Equity
11.71B	12.10B	11.50B	10.65B	9.83B	9.24B
Cash Flow		Free Cash Flow
1.40B	1.77B	1.58B	529.34M	560.25M	-744.16M
	Operating Cash Flow
2.22B	2.54B	2.40B	2.04B	1.40B	1.18B
	Investing Cash Flow
-678.40M	-592.44M	-791.19M	-1.74B	-4.41B	-1.90B
	Financing Cash Flow
-3.39B	-2.79B	-1.89B	278.95M	557.06M	3.21B

Hypera SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPMY, the sentiment is Positive. The current price of 4.45 is above the 20-day moving average (MA) of 4.16, above the 50-day MA of 3.72, and above the 200-day MA of 3.89, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 67.45 is Neutral, neither overbought nor oversold. The STOCH value of 93.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPMY.

Hypera SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	71 Outperform	$1.85B	30.06	6.32%	―	11.82%	―
HYPMY	70 Outperform	$2.79B	18.53	6.94%	3.11%	-25.84%	-55.94%
ALVO	62 Neutral	$3.04B	29.86	128.44%	―	539.47%	―
HCM	58 Neutral	$2.38B	61.41	5.06%	―	-25.48%	-63.36%
AMRX	57 Neutral	$2.35B	―	106.97%	―	13.42%	92.50%
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
DVAX	48 Neutral	$1.18B	64.45	-10.45%	―	24.76%	-783.38%